{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:54:22Z","timestamp":1786118062825,"version":"build-2736575974"},"reference-count":120,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI21C179500"],"award-info":[{"award-number":["HI21C179500"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018749","name":"Korea Brain Research Institute","doi-asserted-by":"publisher","award":["26-BR-02-03"],"award-info":[{"award-number":["26-BR-02-03"]}],"id":[{"id":"10.13039\/100018749","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-16065773"],"award-info":[{"award-number":["RS-2025-16065773"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.tips.2026.06.008","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:22:16Z","timestamp":1783570936000},"page":"871-889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gene therapy for spinocerebellar ataxias"],"prefix":"10.1016","volume":"47","author":[{"given":"Hyemi","family":"Eo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Bok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoungho","family":"Suk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaekwang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0299-1613","authenticated-orcid":false,"given":"Sang Ryong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2026.06.008_bb0005","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1474-4422(23)00068-6","article-title":"Autosomal dominant cerebellar ataxias: new genes and progress towards treatments","volume":"22","author":"Coarelli","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2026.06.008_bb0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.molmed.2024.07.008","article-title":"Emerging therapies in hereditary ataxias","volume":"31","author":"Eisel","year":"2025","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.tips.2026.06.008_bb0015","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12311-025-01856-5","article-title":"Biomarkers in spinocerebellar ataxias","volume":"24","author":"Klockgether","year":"2025","journal-title":"Cerebellum"},{"key":"10.1016\/j.tips.2026.06.008_bb0020","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ng0793-221","article-title":"Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1","volume":"4","author":"Orr","year":"1993","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0025","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ng1196-269","article-title":"Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2","volume":"14","author":"Pulst","year":"1996","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ng1194-221","article-title":"CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1","volume":"8","author":"Kawaguchi","year":"1994","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0035","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000200245","article-title":"Redefining the pathogenic CAG repeat units threshold in CACNA1A for spinocerebellar ataxia type 6","volume":"11","author":"Hatano","year":"2025","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12929-022-00892-1","article-title":"Polyglutamine-expanded ATXN7 alters a specific epigenetic signature underlying photoreceptor identity gene expression in SCA7 mouse retinopathy","volume":"29","author":"Niewiadomska-Cimicka","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.tips.2026.06.008_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000600","article-title":"RNA gain-of-function in spinocerebellar ataxia type 8","volume":"5","author":"Daughters","year":"2009","journal-title":"PLoS Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0050","series-title":"GeneReviews\u00ae","article-title":"Spinocerebellar ataxia type 17","author":"Toyoshima","year":"1993"},{"key":"10.1016\/j.tips.2026.06.008_bb0055","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/mds.29412","article-title":"CAG Repeat expansion in THAP11 is associated with a novel spinocerebellar ataxia","volume":"38","author":"Tan","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.tips.2026.06.008_bb0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/ng0194-9","article-title":"Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA)","volume":"6","author":"Koide","year":"1994","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0065","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41588-024-01719-5","article-title":"A GGC-repeat expansion in ZFHX3 encoding polyglycine causes spinocerebellar ataxia type 4 and impairs autophagy","volume":"56","author":"Figueroa","year":"2024","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0070","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00415-025-13003-5","article-title":"The impact of interrupted ATXN10 expansions on clinical findings of spinocerebellar ataxia type 10","volume":"272","author":"Hasan","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.tips.2026.06.008_bb0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/70493","article-title":"Expansion of a novel CAG trinucleotide repeat in the 5\u2032 region of PPP2R2B is associated with SCA12","volume":"23","author":"Holmes","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0080","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.neurol.2024.03.007","article-title":"Spinocerebellar ataxia 27B (SCA27B), a frequent late-onset cerebellar ataxia","volume":"180","author":"Cl\u00e9ment","year":"2024","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.tips.2026.06.008_bb0085","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ajhg.2009.09.019","article-title":"Spinocerebellar ataxia type 31 is associated with \u201cinserted\u201d penta-nucleotide repeats containing (TGGAA)n","volume":"85","author":"Sato","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0090","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s10038-024-01260-7","article-title":"Hexanucleotide repeat expansion in SCA36 reduces the expression of genes involved in ribosome biosynthesis and protein translation","volume":"69","author":"Morikawa","year":"2024","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0095","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00439-024-02644-7","article-title":"Novel genotype-phenotype correlations, differential cerebellar allele-specific methylation, and a common origin of the (ATTTC)n insertion in spinocerebellar ataxia type 37","volume":"143","author":"Sanchez-Flores","year":"2024","journal-title":"Hum. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0100","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/ng1728","article-title":"Spectrin mutations cause spinocerebellar ataxia type 5","volume":"38","author":"Ikeda","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0105","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/ng.2007.43","article-title":"Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11","volume":"39","author":"Houlden","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1113\/jphysiol.2013.264309","article-title":"Kv3.3 channels harbouring a mutation of spinocerebellar ataxia type 13 alter excitability and induce cell death in cultured cerebellar Purkinje cells","volume":"592","author":"Irie","year":"2014","journal-title":"J. Physiol."},{"key":"10.1016\/j.tips.2026.06.008_bb0115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.mcn.2019.05.005","article-title":"Spinocerebellar ataxia type 14 caused by a nonsense mutation in the PRKCG gene","volume":"98","author":"Shirafuji","year":"2019","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.tips.2026.06.008_bb0120","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/mds.23223","article-title":"An ITPR1 gene deletion causes spinocerebellar ataxia 15\/16: a genetic, clinical and radiological description","volume":"25","author":"Novak","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.tips.2026.06.008_bb0125","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ajhg.2009.04.008","article-title":"IFRD1 is a candidate gene for SMNA on chromosome 7q22-q23","volume":"84","author":"Brkanac","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0130","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/ana.23700","article-title":"Mutations in potassium channel KCND3 cause spinocerebellar ataxia type 19","volume":"72","author":"Duarri","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2026.06.008_bb0135","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/ana.23701","article-title":"Mutations in KCND3 cause spinocerebellar ataxia type 22","volume":"72","author":"Lee","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2026.06.008_bb0140","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1093\/hmg\/ddn283","article-title":"A duplication at chromosome 11q12.2\u201311q12.3 is associated with spinocerebellar ataxia type 20","volume":"17","author":"Knight","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0145","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1093\/brain\/awu202","article-title":"TMEM240 mutations cause spinocerebellar ataxia 21 with mental retardation and severe cognitive impairment","volume":"137","author":"Delplanque","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.tips.2026.06.008_bb0150","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ajhg.2010.10.001","article-title":"Prodynorphin mutations cause the neurodegenerative disorder spinocerebellar ataxia type 23","volume":"87","author":"Bakalkin","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0155","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/a-2205-2402","article-title":"A novel pathogenic variant in the SCA25-related gene expanding the etiology of early-onset and progressive cerebellar ataxia in childhood","volume":"55","author":"Ferrera","year":"2024","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.tips.2026.06.008_bb0160","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1093\/hmg\/dds392","article-title":"A conserved eEF2 coding variant in SCA26 leads to loss of translational fidelity and increased susceptibility to proteostatic insult","volume":"21","author":"Hekman","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0165","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12311-025-01919-7","article-title":"Spinocerebellar ataxia 27 A with episodic ataxia: case series of fibroblast growth factor 14 (FGF14) microdeletions","volume":"24","author":"Conci","year":"2025","journal-title":"Cerebellum"},{"key":"10.1016\/j.tips.2026.06.008_bb0170","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/ng.544","article-title":"Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28","volume":"42","author":"Di Bella","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0175","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1750-1172-7-67","article-title":"Missense mutations in ITPR1 cause autosomal dominant congenital nonprogressive spinocerebellar ataxia","volume":"7","author":"Huang","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.tips.2026.06.008_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100317","article-title":"ELOVL4 mutations that cause spinocerebellar ataxia-34 differentially alter very long chain fatty acid biosynthesis","volume":"64","author":"Gyening","year":"2023","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.tips.2026.06.008_bb0185","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1212\/WNL.0000000000000909","article-title":"Spinocerebellar ataxia 35: novel mutations in TGM6 with clinical and genetic characterization","volume":"83","author":"Guo","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2026.06.008_bb0190","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ajhg.2014.07.001","article-title":"ELOVL5 mutations cause spinocerebellar ataxia 38","volume":"95","author":"Di Gregorio","year":"2014","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0195","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/mds.26059","article-title":"A 7.5-Mb duplication at chromosome 11q21-11q22.3 is associated with a novel spastic ataxia syndrome","volume":"30","author":"Johnson","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.tips.2026.06.008_bb0200","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/jmedgenet-2014-102333","article-title":"A novel missense mutation in CCDC88C activates the JNK pathway and causes a dominant form of spinocerebellar ataxia","volume":"51","author":"Tsoi","year":"2014","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0205","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/mds.26096","article-title":"Do mutations in the murine ataxia gene TRPC3 cause cerebellar ataxia in humans?","volume":"30","author":"Fogel","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.tips.2026.06.008_bb0210","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ajhg.2015.09.007","article-title":"A recurrent mutation in CACNA1G alters Cav3.1 T-type calcium-channel conduction and causes autosomal-dominant cerebellar ataxia","volume":"97","author":"Coutelier","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0215","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000094","article-title":"MME mutation in dominant spinocerebellar ataxia with neuropathy (SCA43)","volume":"2","author":"Depondt","year":"2016","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0220","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajhg.2017.08.005","article-title":"Dominant mutations in GRM1 cause spinocerebellar ataxia type 44","volume":"101","author":"Watson","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0225","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/brain\/awx251","article-title":"Exome sequencing and network analysis identifies shared mechanisms underlying spinocerebellar ataxia","volume":"140","author":"Nibbeling","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.tips.2026.06.008_bb0230","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.cell.2018.02.006","article-title":"A mild PUM1 mutation is associated with adult-onset ataxia, whereas haploinsufficiency causes developmental delay and seizures","volume":"172","author":"Gennarino","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.tips.2026.06.008_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101899","article-title":"The molecular basis of spinocerebellar ataxia type 48 caused by a de novo mutation in the ubiquitin ligase CHIP","volume":"298","author":"Umano","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2026.06.008_bb0240","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac030","article-title":"New spinocerebellar ataxia subtype caused by SAMD9L mutation triggering mitochondrial dysregulation (SCA49)","volume":"4","author":"Corral-Juan","year":"2022","journal-title":"Brain Commun."},{"key":"10.1016\/j.tips.2026.06.008_bb0245","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/brain\/awab407","article-title":"NPTX1 mutations trigger endoplasmic reticulum stress and cause autosomal dominant cerebellar ataxia","volume":"145","author":"Coutelier","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.tips.2026.06.008_bb0250","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-0716-2716-7_1","article-title":"Gene alterations induced by glutamine (Q) encoding CAG repeats associated with neurodegeneration","volume":"2575","author":"Saha","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tips.2026.06.008_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116741","article-title":"Repeat-associated non-AUG translation as a common mechanism for the polyGln ataxias","volume":"45","author":"Banez-Coronel","year":"2026","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2026.06.008_bb0260","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1007\/s12311-024-01723-9","article-title":"Spinocerebellar ataxias: phenotypic spectrum of polyQ versus non-repeat expansion forms","volume":"23","author":"Moura","year":"2024","journal-title":"Cerebellum"},{"key":"10.1016\/j.tips.2026.06.008_bb0265","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/1570159X15666170529104000","article-title":"Calcium signaling, PKC gamma, IP3R1 and CAR8 link spinocerebellar ataxias and Purkinje cell dendritic development","volume":"16","author":"Shimobayashi","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.tips.2026.06.008_bb0270","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s00018-022-04419-7","article-title":"The extra-cerebellar effects of spinocerebellar ataxia type 1 (SCA1): looking beyond the cerebellum","volume":"79","author":"Olmos","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.tips.2026.06.008_bb0275","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/acn3.51875","article-title":"Disease progression of spinocerebellar ataxia types 1, 2, 3, and 6 before and after ataxia onset","volume":"10","author":"Jacobi","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.tips.2026.06.008_bb0280","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaophthalmol.2024.0001","article-title":"ATXN7-related cone-rod dystrophy: the integrated functional evaluation of the cerebellum (CERMOI) study","volume":"142","author":"Nassisi","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.tips.2026.06.008_bb0285","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1056\/NEJMoa2207406","article-title":"Deep intronic FGF14 GAA repeat expansion in late-onset cerebellar ataxia","volume":"388","author":"Pellerin","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2026.06.008_bb0290","doi-asserted-by":"crossref","first-page":"5870","DOI":"10.3390\/ijms22115870","article-title":"Genetic dominant variants in STUB1, segregating in families with SCA48, display in vitro functional impairments indistinctive from recessive variants associated with SCAR16","volume":"22","author":"Pakdaman","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2026.06.008_bb0295","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209749","article-title":"Longitudinal changes of clinical, imaging, and fluid biomarkers in preataxic and early ataxic spinocerebellar ataxia type 2, and 7 carriers","volume":"103","author":"Coarelli","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2026.06.008_bb0300","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/brain\/awaf408","article-title":"Predictive models for ataxia progression and conversion in spinocerebellar ataxia type 1, and 3","volume":"149","author":"Petit","year":"2026","journal-title":"Brain"},{"key":"10.1016\/j.tips.2026.06.008_bb0305","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12311-024-01774-y","article-title":"Quantitative oculomotor and vestibular profile in spinocerebellar ataxia type 6 \u2013 systematic review and meta-analysis","volume":"24","author":"Tarnutzer","year":"2024","journal-title":"Cerebellum"},{"key":"10.1016\/j.tips.2026.06.008_bb0310","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.cortex.2023.09.021","article-title":"Cognitive-affective manifestations since premanifest phases of Spinocerebellar Ataxia type 3\/Machado-Joseph disease","volume":"171","author":"Bolzan","year":"2024","journal-title":"Cortex"},{"key":"10.1016\/j.tips.2026.06.008_bb0315","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/ana.25212","article-title":"Neurochemical abnormalities in premanifest and early spinocerebellar ataxias","volume":"83","author":"Joers","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2026.06.008_bb0320","article-title":"Progression of biological markers in spinocerebellar ataxia type 3: longitudinal analysis of prospective data from the ESMI cohort","volume":"55","author":"Berger","year":"2025","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.tips.2026.06.008_bb0325","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.70325","article-title":"Value of MRI outcomes for preventive and early-stage trials in spinocerebellar ataxias 1 and 3","author":"Rezende","year":"2026","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.tips.2026.06.008_bb0330","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/15459683251395729","article-title":"Pre-frontal cortical activity during gait is altered in pre-manifest and early spinocerebellar ataxia","volume":"40","author":"Mancini","year":"2026","journal-title":"Neurorehabil. Neural Repair"},{"key":"10.1016\/j.tips.2026.06.008_bb0335","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamaneurol.2025.3421","article-title":"Home training for cerebellar ataxias: a randomized clinical trial","volume":"82","author":"Barbuto","year":"2025","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.tips.2026.06.008_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2024.1385280","article-title":"Might patients with cerebellar ataxia benefit from the computer assisted rehabilitation environment (CAREN)? A pilot study focusing on gait and balance","volume":"12","author":"Bonanno","year":"2024","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.tips.2026.06.008_bb0345","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s12311-023-01628-z","article-title":"Efficacy and safety of repetitive transcranial magnetic stimulation in spinocerebellar ataxia type 3: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Qiu","year":"2024","journal-title":"Cerebellum"},{"key":"10.1016\/j.tips.2026.06.008_bb0350","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/mds.28355","article-title":"A chlorzoxazone-baclofen combination improves cerebellar impairment in spinocerebellar ataxia type 1","volume":"36","author":"Bushart","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.tips.2026.06.008_bb0355","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s40120-024-00625-6","article-title":"Video-based kinematic analysis of movement quality in a Phase 3 clinical trial of troriluzole in adults with spinocerebellar ataxia: a post hoc analysis","volume":"13","author":"L\u2019Italien","year":"2024","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.tips.2026.06.008_bb0360","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1212\/WNL.0000000000209018","article-title":"Comparative effectiveness of troriluzole versus untreated natural history cohorts in spinocerebellar ataxia leveraging propensity score matching methods (P6-5.012)","volume":"104","author":"L\u2019Italien","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2026.06.008_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107013","article-title":"Randomized double-blind placebo-controlled trial of the effects of oral trehalose in spinocerebellar ataxia type 3: an interim analysis","volume":"124","author":"Yap","year":"2024","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.tips.2026.06.008_bb0370","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1007\/s12311-024-01714-w","article-title":"Long-term follow-up before and during riluzole treatment in six patients from two families with spinocerebellar ataxia type 7","volume":"23","author":"Suppiej","year":"2024","journal-title":"Cerebellum"},{"key":"10.1016\/j.tips.2026.06.008_bb0375","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.35841","article-title":"Safety and efficacy of acetyl-DL-leucine in certain types of cerebellar ataxia: the ALCAT randomized clinical crossover trial","volume":"4","author":"Feil","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.tips.2026.06.008_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102952","article-title":"L-arginine in patients with spinocerebellar ataxia type 6: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"78","author":"Ishihara","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.tips.2026.06.008_bb0385","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1474-4422(21)00457-9","article-title":"Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"21","author":"Coarelli","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2026.06.008_bb0390","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00401-019-02019-7","article-title":"Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia","volume":"138","author":"N\u00f3brega","year":"2019","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.tips.2026.06.008_bb0395","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1038\/s41467-025-58189-4","article-title":"Mitochondria transplantation transiently rescues cerebellar neurodegeneration improving mitochondrial function and reducing mitophagy in mice","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2026.06.008_bb0400","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12993-022-00194-4","article-title":"Effects of the administration of Elovl5-dependent fatty acids on a spino-cerebellar ataxia 38 mouse model","volume":"18","author":"Balbo","year":"2022","journal-title":"Behav. Brain Funct."},{"key":"10.1016\/j.tips.2026.06.008_bb0405","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2026.06.008_bb0410","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/brain\/awae304","article-title":"Treatment of neurological pathology and inflammation in Machado\u2013Joseph disease through in vivo self-assembled siRNA","volume":"148","author":"Li","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.tips.2026.06.008_bb0415","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf5660","article-title":"An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron","volume":"8","author":"Miyazaki","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2026.06.008_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tips.2026.06.008_bb0425","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s12035-024-04260-y","article-title":"Novel gene therapy approaches for targeting neurodegenerative disorders: focusing on delivering neurotrophic genes","volume":"62","author":"Kumari","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.tips.2026.06.008_bb0430","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature22044","article-title":"Antisense oligonucleotide therapy for spinocerebellar ataxia type 2","volume":"544","author":"Scoles","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.tips.2026.06.008_bb0435","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ana.26713","article-title":"Antisense oligonucleotide silencing reverses abnormal neurochemistry in spinocerebellar ataxia 3 mice","volume":"94","author":"McLoughlin","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2026.06.008_bb0440","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap8677","article-title":"Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7","volume":"10","author":"Niu","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2026.06.008_bb0445","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.ymthe.2024.02.033","article-title":"ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice","volume":"32","author":"Schuster","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tips.2026.06.008_bb0450","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.omtn.2021.11.015","article-title":"Allele-specific targeting of mutant ataxin-3 by antisense oligonucleotides in SCA3-iPSC-derived neurons","volume":"27","author":"Hauser","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.tips.2026.06.008_bb0455","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.3390\/ijms25084354","article-title":"AAV-mediated CAG-targeting selectively reduces polyglutamine-expanded protein and attenuates disease phenotypes in a spinocerebellar ataxia mouse model","volume":"25","author":"Niewiadomska-Cimicka","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2026.06.008_bb0460","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/mt.2013.152","article-title":"Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice","volume":"21","author":"Rodr\u00edguez-Lebr\u00f3n","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tips.2026.06.008_bb0465","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ymthe.2025.10.022","article-title":"Extracellular vesicles-associated AAVs for the treatment of Machado-Joseph disease","volume":"34","author":"Henriques","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tips.2026.06.008_bb0470","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/brain\/awv292","article-title":"Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy","volume":"138","author":"Keiser","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.tips.2026.06.008_bb0475","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ana.24789","article-title":"RNAi prevents and reverses phenotypes induced by mutant human ataxin-1","volume":"80","author":"Keiser","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2026.06.008_bb0480","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/mt.2013.279","article-title":"Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy","volume":"22","author":"Keiser","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tips.2026.06.008_bb0485","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1089\/nat.2021.0020","article-title":"miRNA-mediated knockdown of ATXN3 alleviates molecular disease hallmarks in a mouse model for spinocerebellar ataxia type 3","volume":"32","author":"Nobre","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.tips.2026.06.008_bb0490","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/mt.2013.144","article-title":"Toward RNAi therapy for the polyglutamine disease Machado\u2013Joseph disease","volume":"21","author":"Costa Mdo","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tips.2026.06.008_bb0495","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24299-y","article-title":"Suppressing gain-of-function proteins via CRISPR\/Cas9 system in SCA1 cells","volume":"12","author":"Pappad\u00e0","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2026.06.008_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102317","article-title":"Cas9 editing of ATXN1 in a spinocerebellar ataxia type 1 mice and human iPSC-derived neurons","volume":"35","author":"Fagan","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.tips.2026.06.008_bb0505","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/lifemedi\/lnac020","article-title":"CRISPR\/Cas9-mediated genetic correction reverses spinocerebellar ataxia 3 disease-associated phenotypes in differentiated cerebellar neurons","volume":"1","author":"Song","year":"2022","journal-title":"Life Med."},{"key":"10.1016\/j.tips.2026.06.008_bb0510","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1089\/scd.2017.0209","article-title":"CRISPR\/Cas9-targeted deletion of polyglutamine in spinocerebellar ataxia type 3-derived induced pluripotent stem cells","volume":"27","author":"Ouyang","year":"2018","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.tips.2026.06.008_bb0515","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41398-021-01605-2","article-title":"CRISPR\/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells","volume":"11","author":"He","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2026.06.008_bb0520","article-title":"Genome editing in spinocerebellar ataxia type 3 cells improves Golgi apparatus structure","volume":"15","author":"Wang","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2026.06.008_bb0525","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41434-025-00557-2","article-title":"Gene editing for spinocerebellar ataxia type 3 taking advantage of the human ATXN3L paralog as replacement gene","volume":"32","author":"Rybarikova","year":"2025","journal-title":"Gene Ther."},{"key":"10.1016\/j.tips.2026.06.008_bb0530","first-page":"4432","article-title":"RpA1 ameliorates symptoms of mutant ataxin-1 knock-in mice and enhances DNA damage repair","volume":"25","author":"Taniguchi","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0535","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.neuron.2022.11.017","article-title":"Decreasing mutant ATXN1 nuclear localization improves a spectrum of SCA1-like phenotypes and brain region transcriptomic profiles","volume":"111","author":"Handler","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.tips.2026.06.008_bb0540","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/brain\/awr047","article-title":"Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado\u2013Joseph disease","volume":"134","author":"Nascimento-Ferreira","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.tips.2026.06.008_bb0545","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ymthe.2021.07.012","article-title":"ULK overexpression mitigates motor deficits and neuropathology in mouse models of Machado-Joseph disease","volume":"30","author":"Vasconcelos-Ferreira","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tips.2026.06.008_bb0550","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41401-025-01504-y","article-title":"Intracerebellar upregulation of Rheb(S16H) ameliorates motor dysfunction in mice with SCA2","volume":"46","author":"Kim","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.tips.2026.06.008_bb0555","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.omtm.2022.04.004","article-title":"Combined overexpression of ATXN1L and mutant ATXN1 knockdown by AAV rescue motor phenotypes and gene signatures in SCA1 mice","volume":"25","author":"Carrell","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.tips.2026.06.008_bb0560","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s13023-025-03893-z","article-title":"In vivo applications and toxicities of AAV-based gene therapies in rare diseases","volume":"20","author":"Zhao","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.tips.2026.06.008_bb0565","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/ijms25021050","article-title":"Delivery of adeno-associated virus vectors to the central nervous system for correction of single gene disorders","volume":"25","author":"Daci","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2026.06.008_bb0570","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.947490","article-title":"Selective transduction of cerebellar Purkinje and granule neurons using delivery of AAV-PHP.eB and AAVrh10 vectors at axonal terminal locations","volume":"15","author":"Surdyka","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.tips.2026.06.008_bb0575","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ymthe.2024.11.029","article-title":"Dorsal root ganglion toxicity after AAV intra-CSF delivery of a RNAi expression construct into non-human primates and mice","volume":"33","author":"Hawley","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tips.2026.06.008_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00435","article-title":"Immune responses to central nervous system directed adeno-associated virus gene therapy: does direct CNS delivery make a difference?","volume":"21","author":"Harkins","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.tips.2026.06.008_bb0585","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun. Med. (Lond.)"},{"key":"10.1016\/j.tips.2026.06.008_bb0590","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41587-024-02307-y","article-title":"Tracking-seq reveals the heterogeneity of off-target effects in CRISPR\u2013Cas9-mediated genome editing","volume":"43","author":"Zhu","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tips.2026.06.008_bb0595","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00439-023-02561-1","article-title":"Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells","volume":"142","author":"Hunt","year":"2023","journal-title":"Hum. Genet."},{"key":"10.1016\/j.tips.2026.06.008_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105311","article-title":"Plasma neurofilament light chain predicts cerebellar atrophy and clinical progression in spinocerebellar ataxia","volume":"153","author":"Coarelli","year":"2021","journal-title":"Neurobiol. Dis."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726001628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726001628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:11:14Z","timestamp":1786029074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614726001628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":120,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0165614726001628"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2026.06.008","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for spinocerebellar ataxias","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2026.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}